RxDoctor Payments Data

Luis Gonzalez, MD

Psychiatry · New London, CTNPI 1801863220

Payments from drug & device makers

$1,000in general payments, 2019–2025

Across 56 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$427
  • Neurocrine Biosciences, Inc.$191
  • Teva Pharmaceuticals USA, Inc.$97
  • Sunovion Pharmaceuticals Inc.$79
  • Alkermes, Inc.$77
  • Johnson & Johnson$56
  • plus $74 from 3 others

What the payments were for

  • Food & beverage$1,000100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,000 in reported general payments places this provider in the 75th percentile of 644 psychiatry providers in Connecticut.

See all psychiatry providers in Connecticut

Medicare billing

Part B allowed, 2024
$23,976
Medicare patients
65
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate76$517,201
RexultiBrexpiprazole42$65,270
VraylarCariprazine Hcl27$44,050
Abilify MaintenaAripiprazole11$31,578
Lurasidone Hcl94$16,426
Quetiapine Fumarate317$5,997
Clozapine83$4,777
Fluvoxamine Maleate ErFluvoxamine Maleate11$4,510
Aripiprazole37$3,327
Doxepin Hcl100$2,980
Divalproex Sodium ErDivalproex Sodium51$2,934
Bupropion XlBupropion Hcl94$2,910
Desvenlafaxine Succinate ErDesvenlafaxine Succinate38$2,907
Risperidone OdtRisperidone21$2,881
Duloxetine Hcl87$2,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$191$517,20176 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$31$96,84853 claims
AbbVieVraylar$427$44,05027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 644 psychiatry providers in Connecticut.

Other psychiatry in New London

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →